SEPPIC, Paris   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Paris France (1943)
Status: Left NME R&D (2018)

Organization Overview

First Clinical Trial
2005
NCT00730782
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

SEPPIC

Active Ingredients

Drugs in Phase 3 Trials (1)

cantaloupe (1 trial)

Drugs in Phase 2 Trials (1)

covac-2 (3 trials)

Drugs in Phase 1 Trials (2)

glycovax-002 (1 trial)

pfama-1-fvo[25-545] (1 trial)

Drugs in Other Trials (1)

coriander (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fatigue (Phase 3)

Malaria (Phase 1)

Malaria, Falciparum (Phase 1)

Stress, Psychological (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 5